Neurelis Unveils Clinical Insights on VALTOCO
In an exciting development for the pediatric epilepsy community, Neurelis, Inc. is set to showcase valuable insights from their clinical study design at an upcoming event. This presentation will delve into smart solutions for enrollment challenges faced during the Stellina study, focusing on VALTOCO® (diazepam nasal spray). This study particularly investigates treatments for seizure clusters in children aged 2 to 5 years—a demographic not currently included in the existing treatment indications.
Challenges and Solutions in Pediatric Epilepsy Trials
The admission process for clinical trials can often present unique difficulties, especially in younger patients suffering from treatment-resistant epilepsy. During this presentation, the spotlight is on the findings that reveal these obstacles and potential strategies to navigate them effectively. Dr. Adrian L. Rabinowicz, Chief Medical Officer at Neurelis, emphasizes the importance of this data. "Data from clinical studies of repetitive seizures in early childhood are critical to help advance new treatments for a young population with currently limited alternatives," he stated. Neurelis aims to foster discussion within the child neurology community focused on enhancing health outcomes for children facing epilepsy.
Key Highlights to Expect
Attendees at the annual child neurology gathering can look forward to insights that outline the specific enrollment hurdles encountered and innovative strategies developed to address these challenges. These findings are anticipated to be instrumental in the formation of future clinical protocols in pediatric care.
Details of the Presentation
The engaging poster titled "Challenges Associated with Enrolling Pediatric Patients with Treatment-Resistant Epilepsy Aged 2–5 Years in a Clinical Trial and Lessons Learned for Future Trials" is scheduled to be presented on a dedicated day. The session will occur on a specified Tuesday, targeting both midday and evening audiences, ensuring that various professionals can join in on the conversation.
The Role of the Child Neurology Society
The Child Neurology Society plays a pivotal role in promoting awareness about the significance of child neurologists and the health requirements of children facing chronic neurological conditions. This focus aligns closely with Neurelis' dedication to enhancing medical options for these patients.
About Neurelis: Committed to Neuroscience
Neurelis, Inc. is a dedicated neuroscience company focusing on the research, development, and commercialization of innovative therapeutics for epilepsy and other neurologic disorders characterized by vast unmet medical needs. The U.S. FDA has approved VALTOCO® (diazepam nasal spray) for treating acute seizure clustering episodes distinct from a patient's usual seizure activity in patients aged six years and older. VALTOCO features a proprietary formulation of diazepam that utilizes INTRAVAIL®, a technology designed to enhance noninvasive drug delivery.
Exploring Additional Therapeutics
In addition to VALTOCO, Neurelis is making strides in further developing NRL-1004, an investigational intranasal formulation of olanzapine. This formulation aims to manage acute agitation episodes associated with schizophrenia and bipolar disorder. Furthermore, Neurelis is exploring NRL-1049—an innovative Phase 1 chemical compound targeting cerebral cavernous malformations, a rare central nervous system disorder.
Important Safety Information
When using VALTOCO, it’s essential to exercise caution due to potential risks, including those associated with concomitant use of benzodiazepines and opioids. Health care providers are urged to monitor patients closely for any signs of sedation or respiratory distress. Additionally, the usage of VALTOCO can pose risks concerning dependency and withdrawal, which necessitates careful management, particularly in patients who have been treated for extended periods.
Conclusion and Patient Monitoring
Patients receiving VALTOCO or similar medications should be closely monitored for adverse reactions, including those potentially affecting the central nervous system. Recognizing and addressing these reactions early can significantly reduce adverse outcomes and improve treatment effectiveness.
Frequently Asked Questions
What is VALTOCO used for?
VALTOCO is indicated for the acute treatment of seizure clusters in patients with epilepsy 6 years old and older.
Who will present the clinical study insights?
Dr. Adrian L. Rabinowicz, the Chief Medical Officer at Neurelis, will lead the presentation.
When and where is the presentation scheduled?
The presentation will occur at the Child Neurology Society Annual Meeting on a designated Tuesday during specific hours.
What is Neurelis focused on?
Neurelis is committed to developing treatments for epilepsy and other neurological disorders to address significant unmet medical requirements.
Are there any risks involved with using VALTOCO?
Yes, patients may experience risks related to CNS depression and the potential for abuse, misuse, and dependence on the medication.
